![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » INFRASCAN ANNOUNCES FIRST PATIENTS ENROLL IN CLINICAL TRIAL IN BRAIN HEMATOMA DETECTION
INFRASCAN ANNOUNCES FIRST PATIENTS ENROLL IN CLINICAL TRIAL IN BRAIN HEMATOMA DETECTION
July 26, 2006
InfraScan, a medical device firm specializing in brain injury diagnostic products, announced that more than 15 patients have been enrolled in its clinical trial for hematoma detection. The trials are taking place at Baylor College of Medicine in Houston
and at the Hospital of the University of Pennsylvania in Philadelphia. InfraScan's
lead product, the Infrascanner handheld brain hematoma detector, is a portable
imaging device using near infrared (NIR) technology for the detection of hematoma,
or bleeding in the brain, in people experiencing head trauma.
Genetic
Engineering News
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct